FDA: Civil Service's new diversity plan is welcome - but there's more to do

October 16, 2017

News from the FDA, the union of choice for senior managers and professionals in public service

Commenting on the Civil Service's new Diversity and Inclusion Strategy, Zohra Francis - FDA Equality and Diversity Officer - said:
"The FDA has long called for a greater focus on diversity and inclusion in the civil service, so we welcome today's commitment to charting the progress of BAME and disabled civil servants throughout their careers.
“Coupled with greater transparency in the data, this innovative move should help to provide a more meaningful and measurable way of tracking whether departments are truly reflective of the people they serve. All departments should heed the plan’s commitment to identifying and supporting talented staff, regardless of their background.
"There is, however, much more to do, and the FDA stands ready to work with departments to identify and tackle the barriers under-represented staff face - including divisive performance management systems which can stifle the very talent that the public sector should be nurturing.
"We look forward to seeing a step change in the way the civil service approaches inclusion, and we will be working with our diversity networks and growing BAME membership to hold departments to account as they put this new plan into action.”

Notes for editors
1. The FDA is the trade union for the UK's senior public servants and professionals at grade HEO and above. FDA membership includes more than 18,000 senior civil servants, diplomats, Government policy advisors, prosecutors, tax professionals, economists, solicitors and other professionals working across Government and the NHS.

2. The FDA (formerly the First Division Association) should be referred to simply as "The FDA" and can be described as "the senior public servants' union".

3. The FDA can be found on Twitter @FDA_union and at www.fda.org.uk. General Secretary Dave Penman tweets as @FDAGenSec.

4. For further information contact the FDA Communications team on 020 7401 5589.